Search results
Get Ready for ASCO 2024 Annual Meeting | Newswise
Newswise· 22 hours agoASCO, the largest event in cancer research, is approaching on May 31st. ASCO offers tailored scientific events for oncology professionals, patient advocate
Rakuten Medical Announces Poster Presentation and Booth Exhibition at ASCO 2024 Annual Meeting
WJTV Jackson· 4 hours ago...precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced that it will present a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in Chicago, Illinois from May 31 through June 4, 2024.
CG Pharmaceuticals, Inc. to Present at the 2024 ASCO Annual Meeting in Chicago on June 1st
CBS 47 Fresno· 4 days agoCommencement of treatment for the first patient of Phase 2 began on January 9th, 2024, and the study will continue to recruit patients in approximately 25 institutions throughout ...
...) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral...
WTNH-TV New Haven· 2 days agoLin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting in Chicago. Dr. Shen will...
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting ...
WKRN Nashville· 3 days agoGC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the ...
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
GuruFocus.com via Yahoo Finance· 2 days ago2024 and into 2025, potentially establishing the drugs efficacy and safety profile across various tumor types. Additionally, the final results from the Phase 1 study of azenosertib ...
NovoCure (NVCR) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 7 days agoKey opinion leaders have validated our enthusiasm for the METIS results. Last week, we were pleased to announce that the METIS trial has been accepted as...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
WKBN 27 Youngstown· 3 days agoASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over ...
Tip Sheet: Funding awarded to two ovarian cancer research projects, progress towards liquid biopsies...
Newswise· 7 days agoMay is the awareness month for brain, bladder, melanoma and skin cancers...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 15 hours agoInitial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025Presented real world evidence on the
